BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 16978958)

  • 1. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
    Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
    Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy with aromatase inhibitors in postmenopausal, estrogen receptor- positive breast cancer patients: upfront or sequential?
    Dediu M; Median D; Alexandru A; Vremes G; Gal C; Gongu M
    J BUON; 2009; 14(3):375-9. PubMed ID: 19810126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase inhibitor-associated arthralgia syndrome.
    Burstein HJ
    Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Menopausal symptoms and adjuvant therapy-associated adverse events.
    Hadji P
    Endocr Relat Cancer; 2008 Mar; 15(1):73-90. PubMed ID: 18310277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors and musculoskeletal symptoms.
    Khanduri S; Dodwell DJ
    Breast; 2008 Feb; 17(1):76-9. PubMed ID: 17822901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
    Kimmick GG; Lovato J; McQuellon R; Robinson E; Muss HB
    Breast J; 2006; 12(2):114-22. PubMed ID: 16509835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.
    Cella D; Fallowfield LJ
    Breast Cancer Res Treat; 2008 Jan; 107(2):167-80. PubMed ID: 17876703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating trial data into patients benefits: making the right choice.
    Chlebowski RT
    Breast; 2008 Apr; 17 Suppl 3():S9-15. PubMed ID: 18367397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
    Schwartzberg LS; Cobb P; Senecal F; Henry D; Kulig K; Walker MS; Houts AC; Stepanski EJ
    Breast; 2009 Apr; 18(2):78-83. PubMed ID: 19342237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.
    Ryan PD; Goss PE
    Oncologist; 2006; 11(7):718-31. PubMed ID: 16880231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectively nursing patients receiving aromatase inhibitor therapy.
    Wengström Y
    Breast; 2008 Jun; 17(3):227-38. PubMed ID: 18077168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant endocrine therapy for early breast cancer.
    Andreetta C; Smith I
    Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
    Dent SF; Gaspo R; Kissner M; Pritchard KI
    Breast Cancer Res Treat; 2011 Apr; 126(2):295-310. PubMed ID: 21249443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing the toxicities of the aromatase inhibitors.
    Mortimer JE
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):56-60. PubMed ID: 20019610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations.
    Coleman RE; Bolten WW; Lansdown M; Dale S; Jackisch C; Merkel D; Maass N; Hadji P
    Cancer Treat Rev; 2008 May; 34(3):275-82. PubMed ID: 18082328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter.
    Gandhi S; Verma S
    Breast Cancer Res Treat; 2007 Nov; 106(1):1-9. PubMed ID: 17211535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
    J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.